• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种包含O型口蹄疫病毒VP1的G-H环区域共有序列和一个通用T辅助表位的合成肽可诱导产生肽特异性抗体,但无法保护牛免受病毒攻击。

A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge.

作者信息

Rodriguez Luis L, Barrera Jose, Kramer Ed, Lubroth Juan, Brown Fred, Golde William T

机构信息

Agricultural Research Service, US Department of Agriculture, Plum Island Animal Disease Center, Greenport, NY 11944, USA.

出版信息

Vaccine. 2003 Sep 8;21(25-26):3751-6. doi: 10.1016/s0264-410x(03)00364-5.

DOI:10.1016/s0264-410x(03)00364-5
PMID:12922108
Abstract

A pilot study was carried out in cattle to determine the immunogenicity of a synthetic consensus peptide comprising the G-H loop region of foot-and-mouth disease virus (FMDV) type-O VP1 and a non-VP1 T-helper (Th) epitope. Cattle vaccinated intramuscularly either once (n = 5) or twice (n = 4) with 50 microg of the peptide preparation at a 21-day interval developed antibodies to the peptide as determined by ELISA with the exception of one steer that received a single dose. However, neutralizing antibody titers against FMDV type-O were modest and all animals presented with clinical FMD signs upon challenge 21 days after the last vaccination. In contrast, four of the five animals inoculated with an inactivated FMD type-O commercially prepared vaccine developed neutralizing antibodies and were fully protected against clinical disease following virus challenge 21 days post-vaccination (dpv). Nucleotide sequence comparison of the VP1 region between the challenge virus and RT-PCR products recovered from a lesion of the peptide-vaccinated animal with the highest neutralizing antibody titer 5 days post-challenge (dpc) showed no evidence for selection of a neutralization-resistant mutant. We conclude that although the synthetic peptide induced an antibody response in cattle, it failed to confer protection against FMDV challenge.

摘要

在牛身上开展了一项初步研究,以确定一种合成共有肽的免疫原性,该肽包含口蹄疫病毒(FMDV)O型VP1的G-H环区域和一个非VP1辅助性T细胞(Th)表位。以21天的间隔对牛进行一次(n = 5)或两次(n = 4)肌肉注射50微克肽制剂,除一头接受单剂量的公牛外,通过ELISA测定,其余牛均产生了针对该肽的抗体。然而,针对FMDV O型的中和抗体效价适中,并且所有动物在最后一次接种疫苗21天后受到攻击时均出现了口蹄疫临床症状。相比之下,接种市售灭活FMD O型疫苗的五只动物中有四只产生了中和抗体,并且在接种疫苗后21天(dpv)受到病毒攻击后完全免受临床疾病的侵害。对攻击病毒与在攻击后5天(dpc)中和抗体效价最高的肽疫苗接种动物损伤处回收的RT-PCR产物之间的VP1区域进行核苷酸序列比较,未发现选择中和抗性突变体的证据。我们得出结论,尽管合成肽在牛中诱导了抗体反应,但它未能提供针对FMDV攻击的保护作用。

相似文献

1
A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge.一种包含O型口蹄疫病毒VP1的G-H环区域共有序列和一个通用T辅助表位的合成肽可诱导产生肽特异性抗体,但无法保护牛免受病毒攻击。
Vaccine. 2003 Sep 8;21(25-26):3751-6. doi: 10.1016/s0264-410x(03)00364-5.
2
Vesicular Stomatitis Virus glycoprotein G carrying a tandem dimer of Foot and Mouth Disease Virus antigenic site A can be used as DNA and peptide vaccine for cattle.水疱性口炎病毒糖蛋白 G 携带口蹄疫病毒抗原位点 A 的串联二聚体可作为牛的 DNA 和肽疫苗使用。
Antiviral Res. 2011 Nov;92(2):219-27. doi: 10.1016/j.antiviral.2011.08.006. Epub 2011 Aug 26.
3
Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep.高免疫原性 O1 曼萨那单价疫苗对绵羊感染 O/SEA/Mya-98 谱系口蹄疫病毒的效力。
Antiviral Res. 2017 Sep;145:114-122. doi: 10.1016/j.antiviral.2017.07.020. Epub 2017 Aug 3.
4
Efficacy of synthetic peptide candidate vaccines against serotype-A foot-and-mouth disease virus in cattle.合成肽候选疫苗对牛口蹄疫病毒血清型 A 的效力。
Appl Microbiol Biotechnol. 2015 Feb;99(3):1389-98. doi: 10.1007/s00253-014-6129-1. Epub 2014 Nov 9.
5
Marker vaccine potential of a foot-and-mouth disease virus with a partial VP1 G-H loop deletion.口蹄疫病毒 VP1 G-H 环缺失部分具有标记疫苗潜力。
Vaccine. 2010 Apr 26;28(19):3428-34. doi: 10.1016/j.vaccine.2010.02.074. Epub 2010 Mar 1.
6
Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response.表达非结构蛋白 2B 的腺病毒载体口蹄疫衣壳亚单位疫苗的效力增加与特定的 T 细胞反应有关。
Vaccine. 2011 Nov 28;29(51):9431-40. doi: 10.1016/j.vaccine.2011.10.037. Epub 2011 Oct 24.
7
Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge.一项使用同源攻毒法对牛进行腺病毒载体口蹄疫病毒A24亚型亚单位疫苗的多项效力研究。
Vaccine. 2016 Jun 8;34(27):3214-3220. doi: 10.1016/j.vaccine.2015.12.018. Epub 2015 Dec 18.
8
Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine.使用 ENABL®佐剂提高腺病毒载体口蹄疫病毒 A 型亚单位疫苗的效力。
Vaccine. 2018 Feb 14;36(8):1078-1084. doi: 10.1016/j.vaccine.2018.01.026. Epub 2018 Jan 20.
9
The VP1 G-H loop hypervariable epitope contributes to protective immunity against Foot and Mouth Disease Virus in swine.VP1 G-H 环高变区表位有助于猪抵抗口蹄疫病毒的保护性免疫。
Vaccine. 2019 Jun 6;37(26):3435-3442. doi: 10.1016/j.vaccine.2019.05.019. Epub 2019 May 10.
10
Duration of protection and humoral immunity induced by an adenovirus-vectored subunit vaccine for foot-and-mouth disease (FMD) in Holstein steers.牛传染性口蹄疫(FMD)腺病毒载体亚单位疫苗诱导的保护持续时间和体液免疫。
Vaccine. 2019 Sep 30;37(42):6221-6231. doi: 10.1016/j.vaccine.2019.08.017. Epub 2019 Sep 5.

引用本文的文献

1
Foot-and-mouth disease virus vaccine with VP1 G-H loop substitution of the Cathay strain broadens antigen spectrum.具有中国株VP1 G-H环替换的口蹄疫病毒疫苗拓宽了抗原谱。
Appl Microbiol Biotechnol. 2025 Sep 11;109(1):199. doi: 10.1007/s00253-025-13561-8.
2
Remapping the spatial distribution of neutralizing sites and their immunodominance on the capsid of different topotypes of FMDV serotype O by site-directed competitive ELISA for detection of neutralizing antibodies.通过定点竞争酶联免疫吸附测定法检测中和抗体,重新绘制O型口蹄疫病毒不同拓扑型衣壳上中和位点的空间分布及其免疫显性。
Microbiol Spectr. 2025 Jun 3;13(6):e0334424. doi: 10.1128/spectrum.03344-24. Epub 2025 May 15.
3
Virulence and Immune Evasion Strategies of FMDV: Implications for Vaccine Design.
口蹄疫病毒的毒力与免疫逃逸策略:对疫苗设计的启示
Vaccines (Basel). 2024 Sep 19;12(9):1071. doi: 10.3390/vaccines12091071.
4
Foot-and-mouth disease virus localisation on follicular dendritic cells and sustained induction of neutralising antibodies is dependent on binding to complement receptors (CR2/CR1).口蹄疫病毒在滤泡树突状细胞上的定位和持续诱导中和抗体的产生依赖于与补体受体(CR2/CR1)的结合。
PLoS Pathog. 2022 May 5;18(5):e1009942. doi: 10.1371/journal.ppat.1009942. eCollection 2022 May.
5
Avidity of Polyclonal Antibodies to Foot-and-Mouth Disease Virus in Bovine Serum Measured Using Bio-Layer Interferometry.利用生物层干涉测量法测定牛血清中抗口蹄疫病毒多克隆抗体的亲合力。
Viruses. 2022 Mar 29;14(4):714. doi: 10.3390/v14040714.
6
Swine T-Cells and Specific Antibodies Evoked by Peptide Dendrimers Displaying Different FMDV T-Cell Epitopes.展示不同口蹄疫病毒T细胞表位的肽树枝状聚合物引发的猪T细胞和特异性抗体
Front Immunol. 2021 Feb 3;11:621537. doi: 10.3389/fimmu.2020.621537. eCollection 2020.
7
A Highly Conserved Epitope (RNNQIPQDF) of Induced a Group-Specific Antiserum: A Bioinformatics-Predicted Model with Pan-PTV Potential.一个高度保守的表位(RNNQIPQDF)诱导了一种具有泛 PTV 潜力的组特异性抗血清:生物信息学预测模型。
Viruses. 2020 Oct 29;12(11):1225. doi: 10.3390/v12111225.
8
Immunogenicity of a Dendrimer BT Peptide Harboring a T-Cell Epitope From FMDV Non-structural Protein 3D.携带口蹄疫病毒非结构蛋白3D中T细胞表位的树枝状聚合物BT肽的免疫原性
Front Vet Sci. 2020 Aug 11;7:498. doi: 10.3389/fvets.2020.00498. eCollection 2020.
9
Recombinant vesicular stomatitis virus glycoprotein carrying a foot-and-mouth disease virus epitope as a vaccine candidate.携带口蹄疫病毒表位的重组水疱性口炎病毒糖蛋白作为疫苗候选物。
J Vet Med Sci. 2020 Aug 28;82(8):1155-1159. doi: 10.1292/jvms.19-0559. Epub 2020 Jul 23.
10
A Single Dose of Dendrimer BT Peptide Vaccine Partially Protects Pigs against Foot-and-Mouth Disease Virus Infection.单剂量树枝状大分子BT肽疫苗可部分保护猪免受口蹄疫病毒感染。
Vaccines (Basel). 2020 Jan 10;8(1):19. doi: 10.3390/vaccines8010019.